ArticleAmerican journal of translational research2026
Effects of protein-supportive therapy on maternal and neonatal outcomes in patients with nephrotic syndrome during pregnancy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy and safety of protein-supportive therapy in patients with nephrotic syndrome during pregnancy.
methodsThis retrospective study included 314 women with moderate to severe preeclampsia, of whom 152 were diagnosed with nephrotic syndrome during pregnancy. Patients were divided into a treatment group (n=82) and a control group (n=70) according to treatment regimen. The treatment group received supplemental human albumin (daily dose < 15 g) in addition to blood pressure control, while the control group received only routine antihypertensive treatment. Blood pressure levels, 24-hour urinary protein, serum total protein, albumin, creatinine (Cr), uric acid (UA), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), lipid levels, liver function indicators, coagulation function, and inflammatory markers were compared between the two groups before and after treatment. Edema resolution time, length of hospital stay, pregnancy complications, and delivery method were observed; fetal birth weight, Apgar score, and perinatal mortality were also assessed. Adverse reactions during treatment were recorded.
resultsSignificant differences were observed in diastolic blood pressure, systolic blood pressure, 24-hour urinary protein, serum total protein levels, and renal function indicators before and after treatment in the treatment group (all P < 0.05). The control group mainly experienced decreased blood pressure and serum total protein levels (both P < 0.05). Post-treatment comparisons between groups showed that 24-hour urinary protein levels in the treatment group increased, significantly higher than in the control group, while serum total protein and albumin levels were significantly higher in the treatment group (all P < 0.05). Neonatal birth weight and Apgar scores were significantly higher in the treatment group (P < 0.05). Edema resolution time was longer in the treatment group than in the control group (P < 0.05). No serious allergic reactions or infections occurred during treatment.
conclusionProtein-supportive therapy can improve hypoalbuminemia and fetal outcomes, but it may increase urinary protein excretion and edema resolution time. Thus, the benefits and risks should be carefully weighed in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.